Rigel Pharmaceuticals Azioni (NASDAQ: RIGL)

Rigel Pharmaceuticals (NASDAQ:RIGL) Azioni

RIGEL PHARMACEUTICALS INC

Rigel Pharmaceuticals

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals Inc

WIIM

RIGL

RIGL stock has given up its prior gain. Rigel Pharmaceuticals shares were trading higher after the company reported Q1 financial results and beat its EPS and sales estimates.

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday.
Shares of Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS and GAAP EPS guidance. Also, the company issued FY25 sales guidance <a href="https://www.benzinga.com/quote/ROK/earnings">above estimates</a>.
Sales fell 6% year over year (Y/Y) and slid 4% organically to $2.001 billion, versus the consensus of $1.96 billion. Total ARR grew 8% Y/Y. Adjusted EPS was $2.45 (-2% Y/Y), above the analyst consensus of $2.09.
Rockwell Automation shares jumped 12.4% to $284.30 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) shares jumped 46% to $9.28 following a first-quarter revenue and EPS beat. Additionally, the company raised its FY25 sales guidance above estimates.</li>
<li>NerdWallet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRDS#NASDAQ">NRDS</a>) gained 29.7% to $10.98 following a first-quarter revenue beat and after the company issued second-quarter revenue guidance above estimates.</li>
<li>Angi Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) gained 29% to $14.47 after the company reported better-than-expected quarterly financial results.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) gained 29% to $0.9049 after the company reported first-quarter financial results and beat its adjusted EPS and revenue estimates.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares jumped 28.8% to $16.84 after the company reported better-than-expected first-quarter financial results and issued FY25 sales guidance above estimates.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) rose 27% to $0.8966 after the company reported first-quarter financial results and beat its adjusted EPS and revenue estimates.</li>
<li>The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) gained 23.6% to $16.83 after the company reported better-than-expected first-quarter financial results.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) gained 23.3% to $6.28 after the company reported better-than-expected quarterly financial results.</li>
<li>Rigel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) gained 23.1% to $22.48 after the company reported upbeat quarterly financial results.</li>
<li>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares rose 21.6% to $140.38 after the company reported better-than-expected quarterly financial results and raised its FY25 guidance.</li>
<li>Elanco Animal Health Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NASDAQ">ELAN</a>) gained 16.5% to $11.09 after the company reported better-than-expected first-quarter financial results and raised its FY25 revenue guidance above estimates. Also, the company issued FY25 adjusted EPS guidance with its midpoint above estimates.</li>
<li>Resideo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REZI#NYSE">REZI</a>) shares rose 14.2% to $19.94 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>ZEEKR Intelligent Technology Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) gained 10.5% to $24.97.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) gained 10% to $28.31 after the company reported better-than-expected fourth-quarter financial results and issued FY26 guidance above estimates.</li>
<li>The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) shares rose 9.3% to $100.81 after the company reported better-than-expected quarterly results.</li>
<li>Voya Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) gained 8.2% to $65.22 after the company reported better-than-expected first-quarter financial results.</li>
<li>Grand Canyon Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) rose 7% to $198.49 following upbeat quarterly earnings.</li>
<li>BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) gained 4.5% to $30.32 following better-than-expected quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45251088/top-3-financial-stocks-that-may-plunge-in-may">Top 3 Financial Stocks That May Plunge In May</a> </li>
</ul>
Photo via Shutterstock

News

Intraday Update

Markets

Movers

Trading Ideas

ANGI

ELAN

EOSE

LOPE

NRDS

OPEN

OSCR

PRCH

REZI

VOYA

Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $20 to $23.

Price Target

Analyst Ratings

Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $23

Rigel Pharmaceuticals shares are trading higher after the company reported Q1 financial results and beat its EPS and sales estimates.

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 88.9% to $2.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock moved upwards by 45.13% to $0.8. The company's market cap stands at $2.8 million. </li>
<li>Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares moved upwards by 21.56% to $140.3. The company's market cap stands at $7.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) shares rose 21.09% to $22.11. The market value of their outstanding shares is at $389.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock rose 19.56% to $3.85. The market value of their outstanding shares is at $21.5 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares moved upwards by 17.68% to $0.56. The company's market cap stands at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 55.0% to $0.08 during Wednesday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 24.35% to $5.5. The company's market cap stands at $506.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock decreased by 20.22% to $0.75. The company's market cap stands at $2.9 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock declined by 18.08% to $38.3. The company's market cap stands at $3.7 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) stock decreased by 14.41% to $1.13. The market value of their outstanding shares is at $719.6 million. As per the press release, Q1 earnings came out today. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) shares fell 12.54% to $91.7. The company's market cap stands at $6.2 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GERN

KZIA

LNTH

MYGN

SRPT

TOVX

ZVSA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) affirms FY2025 sales outlook from $200.00 million-$210.00 million to $200.00 million-$210.00 million vs $228.79 million estimate.

Guidance

Rigel Pharmaceuticals Affirms FY2025 Sales Guidance of $200.00M-$210.00M vs $228.79M Est

<h3>Gainers</h3>
<ul>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares rose 15.1% to $3.66 during Tuesday's after-market session. The company's market cap stands at $19.5 million. </li>
<li>Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) shares increased by 11.11% to $4.9. The market value of their outstanding shares is at $68.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) shares moved upwards by 10.89% to $20.25. The market value of their outstanding shares is at $356.7 million. The company's, Q1 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) stock moved upwards by 10.0% to $0.33. The company's market cap stands at $14.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 9.84% to $0.42. The company's market cap stands at $11.8 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares rose 9.35% to $0.49. The market value of their outstanding shares is at $71.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock fell 20.7% to $37.0 during Tuesday's after-market session. The company's market cap stands at $3.6 billion. The company's, Q1 earnings came out today. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 18.44% to $5.93. The company's market cap stands at $546.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares decreased by 16.87% to $0.78. The market value of their outstanding shares is at $3.0 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock fell 8.82% to $3.0. The company's market cap stands at $4.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 8.49% to $1.51. The market value of their outstanding shares is at $2.9 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 8.48% to $1.08. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

BDSX

CPIX

EVOK

HBIO

LPCN

ONMD

THAR

12 Health Care Stocks Moving In Tuesday's After-Market Session

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 financial results.

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.09 by 600 percent. This is a 226 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $53.30 million which beat the analyst consensus estimate of $43.87 million by 21.50 percent. This is a 80.47 percent increase over sales of $29.53 million the same period last year.

Earnings

Rigel Pharmaceuticals Q1 EPS $0.63 Beats $0.09 Estimate, Sales $53.30M Beat $43.87M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Rigel Pharmaceuticals will report an earnings per share (EPS) of $0.09.
Investors in Rigel Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.25 in the last quarter, leading to a 8.11% drop in the share price on the following day.
Here's a look at Rigel Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.55</td>
<td>0.06</td>
<td>-0.29</td>
<td>-0.3</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.80</td>
<td>0.70</td>
<td>-0.06</td>
<td>-0.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>43.0%</td>
<td>6.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746475376_0.png" alt="eps graph" />
<h3>Tracking Rigel Pharmaceuticals's Stock Performance</h3>
Shares of Rigel Pharmaceuticals were trading at $19.36 as of May 02. Over the last 52-week period, shares are up 60.59%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/RIGL/earnings">To track all earnings releases for Rigel Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Rigel Pharmaceuticals's Earnings

Biotech

Legal

General

Rigel Announces Settlement Agreement With Annora Resolving TAVALISSE Patent Litigation

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and raises the price target from $49 to $55.

Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $55

B. Riley Securities analyst Kalpit Patel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $20 to $24.

B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $24

The three major indices were mostly flat in midday trading Wednesday with the S&amp;P 500 and Nasdaq slightly under the flatline and the Dow Jones<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44143660/howard-lutnick-says-president-definitely-thinks-theres-a-bitcoin-strategic-reserve"> up 39 points.&nbsp;</a>
Wall Street digested mixed economic data after the ISM Services PMI<a href="https://www.benzinga.com/news/econ-s/25/03/44143666/us-services-sector-unexpectedly-expands-in-february-despite-slowing-job-growth"> price index indicated</a> strong growth in the services sector, but the ADP employment report came in well below forecasts and added the fewest jobs in seven months. 
Traders awaited further <a href="https://www.benzinga.com/news/25/03/44143647/trump-considering-tariff-relief-for-mexico-canada-commerce-secretary-lutnick-says">developments on trade policy</a> after Commerce Secretary Howard Lutnick appeared on Bloomberg Television on Wednesday. Lutnick said President Donald Trump would likely make a decision on possible tariff relief for Mexico and Canada Wednesday afternoon.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a>
The yield on the 10-year US Treasury note was at 4.23% on Wednesday, trimming declines from the morning after expansion in the services sector, reflected by the ISM PMI easing concerns on lower growth. However, yields remained near four-month lows touched earlier in the week.  The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.24%.  
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was up 1% on Wednesday, and up nearly 5% on the week, as investors look forward to President Trump's White House crypto summit on Friday.&nbsp;
<h2 class="wp-block-heading">Wednesday's Performance In Major U.S. Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,207.74</td>
<td>-0.43%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,756.29</td>
<td>-0.38%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,470.06</td>
<td>-0.12%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,075.09</td>
<td>-0.21%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.43% at $574.36. </li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.14% at $424.98. </li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.58% to $492.67. </li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)&nbsp;slid 0.59% to $205.22. </li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)&nbsp;was down 0.19% to $207.85. </li>
<li>The&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)&nbsp;was down 3.31% to $84.09. </li>
</ul>
<h2 class="wp-block-heading">Wednesday&#8217;s Stock Movers:&nbsp;</h2>
Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) shares plunged Wednesday after the company&#8217;s weak outlook overshadowed its <a href="https://www.benzinga.com/news/earnings/25/03/44142510/abercrombie-q4-earnings-beat-overshadowed-by-cautious-q1-outlook-stock-plunges">better-than-expected</a> fourth-quarter results. The company said it expects first-quarter EPS in the range of $1.25 to $1.45 versus the $2.01 estimate.
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>ChargePoint Holdings, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) <a href="https://www.benzinga.com/quote/chpt" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/quote/chpt" target="_blank" rel="noreferrer noopener"></a></li>
<li>Ross Stores, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) </li>
<li>Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) </li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) &nbsp;</li>
<li>Box, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) </li>
<li>Sociedad Quimica y Minera S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) </li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) </li>
<li>Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>)</li>
<li>Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) </li>
<li>Arbe Robotics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) </li>
</ul>
Companies reporting after Wednesday&#8217;s closing bell include:&nbsp;
<ul>
<li>Grindr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) </li>
<li>LendingTree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) </li>
<li>MongoDB, Inc. (NAS+DAQ:MDB) </li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) </li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) </li>
<li>Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) </li>
<li>Victorias Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) </li>
<li>Fortuna Mining Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) </li>
</ul>
Read Next:<a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying" target="_blank" rel="noreferrer noopener">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying" target="_blank" rel="noreferrer noopener">Markets Tank After Trump Confirms More Tariffs: Here's What Wall Street Is Saying</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Market Summary

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Politics

Global

Tech

ETFs

$BTC

ARBE

AVAV

CHPT

CRWD

SPDR Dow Jones Industrial Average ETF Trust

GRND

MRVL

RGTI

ROST

STEM

iShares Trust Barclays 20+ Year Treasury Bond Fund

TREE

VSCO

Select Sector SPDR-Consumer Discretionary

Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic Data: What's Driving Markets Wednesday?

Rigel Pharmaceuticals shares are trading lower. The company reported Q4 financial results.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and maintains $57 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) affirms FY2025 sales outlook from $200.00 million-$210.00 million to $200.00 million-$210.00 million vs $200.70 million estimate.

Rigel Pharmaceuticals Affirms FY2025 revenue Guidance of $200.00M-$210.00M vs $200.70M Est

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.47 by 70.21 percent. This is a 1900 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $57.60 million which beat the analyst consensus estimate of $51.73 million by 11.34 percent. This is a 60.92 percent increase over sales of $35.79 million the same period last year.

Earnings Beats

Rigel Pharmaceuticals Q4 EPS $0.80 Beats $0.47 Estimate, Sales $57.60M Beat $51.73M Estimate

U.S. stocks plunged Tuesday as President Donald Trump&#8216;s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44110685/markets-see-hardly-a-flesh-wound-so-far-but-centurys-biggest-trade-war-looms-says-bob-elliott">global trade tensions.</a>
The Dow Jones Industrial Average fell 1.8%, extending Monday&#8217;s sharp decline of nearly 650 points and heading towards its worst performance of 2025. The S&amp;P 500 decreased by 1.7%, while the Nasdaq Composite dropped 1.9%, putting it<a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44108913/tariffs-trump-tumult-how-to-trade-this-volatility-vix-surge"> on course</a> to enter correction territory, defined as a 10% drop from its recent peak.&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a>
<a href="https://www.benzinga.com/25/03/44102599/canadian-pm-justin-trudeau-retaliates-with-25-tariffs-on-us-goods-amid-escalating-trade-war">Affected countries</a> announced retaliatory measures, further dampening investor sentiment.
China announced retaliatory tariffs of up to 15% on certain U.S. products, including chicken, wheat, corn, and cotton. Canadian Prime Minister Justin Trudeau declared that Canada would impose a 25% tariff on U.S. goods. Mexican President Claudia Sheinbaum stated that Mexico would respond with tariffs and other measures, to be announced on Sunday.
The yield on the US 10-year Treasury note fell to 4.13% on Tuesday, its lowest level since October 2024. Markets are now pricing in three quarter-point rate cuts by the Federal Reserve in 2025, according to data from CME FedWatch. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) slipped 0.58%. 
Natural gas futures rose more than 8% on Tuesday, above $4.45/MMBtu, the highest since December 2022. Stockpiles remain below the five-year average due to earlier extreme cold in the U.S. while LNG export flows have reached record levels. The United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) ETF climbed 8.5%.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continued Monday's decline to trade below the $84,000 mark, leading crypto markets lower. 
<h2 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,175.89</td>
<td>-0.99%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,772.73</td>
<td>-1.32%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,535.92</td>
<td>-1.52%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,064.42</td>
<td>-1.81%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 1.24% to $576.36. </li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 1.45% at $425.81.&nbsp;</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.8% to $493.08.&nbsp;</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) slid 1.1% to $205.00.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) was down 2.17% to $207.38.&nbsp;</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) was down 1.06% to $86.87.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Tuesday's Stock Movers:&nbsp;</h2>
Shares of Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), bucked the market trend, surging 18% after the company reported&nbsp;better-than-expected <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/03/44108947/okta-stock-is-surging-tuesday-heres-why">financial results</a> on Monday. 
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)&nbsp;</li>
<li>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)&nbsp;</li>
<li>B. Riley Financial, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>)&nbsp;</li>
<li>Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>)&nbsp;</li>
<li>NuScale Power Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>)&nbsp;</li>
<li>GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>)&nbsp;</li>
<li>Curaleaf Hldgs Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>)&nbsp;</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>)&nbsp;</li>
<li>Emergent BioSolutions Inc.&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)&nbsp;</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)&nbsp;</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>)&nbsp;</li>
</ul>
Companies reporting after Tuesday's closing bell include:&nbsp;
<ul>
<li>ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>)</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) </li>
<li>Rigel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) </li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) </li>
<li>Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) </li>
<li>Sociedad Quimica y Minera S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) </li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) </li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) </li>
</ul>
Read Next:<a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a></li>
</ul>
Image: Shutterstock

ASTS

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

DAVE

GTLB

OKTA

RILY

Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday?

Press Releases

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Rigel Provides Business Update and 2025 Outlook

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Comments

Rigel Pharmaceuticals

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO